Oncological results of oncoplastic breast-conserving surgery: Long term follow-up of a large series at a single institution: A matched-cohort analysis. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: De Lorenzi, F.; Hubner, G.; Rotmensz, N.; Bagnardi, V.; Loschi, P.; Maisonneuve, P.; Venturino, M.; Orecchia, R.; Galimberti, V.; Veronesi, P.; Rietjens, M.
• Is Part Of: European journal of surgical oncology. Volume 42:Issue 1(2016:Jan.)
• Page Start: 71
• Page End: 77
• Publication Date: 2016-01
• Subjects: Oncoplastic surgery -- Local recurrence -- Invasive breast cancer -- Conservative treatment; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2015.08.160
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Purpose: Oncoplastic surgery is a well-established discipline that combines conserving treatment for breast cancer with immediate plastic reconstruction. Although widely practiced, the oncologic outcomes of this combined approach are reported only in small series. The aim of the present paper is to assess the safety of oncoplastic surgery for invasive primary breast cancer. Methods: We compared 454 consecutive patients who underwent an oncoplastic approach between 2000 and 2008 for primary invasive breast tumors ( study group ) with twice the number of patients who received conservation alone in the same interval time ( control group ). Disease free survival and overall survival were estimated using the Kaplan–Meier method. The log-rank test was used to assess differences between groups. Results: The median follow-up was 7.2 years. The overall survival is similar within the two groups, being 91.4% and 91.3% at 10-yr in the study group and in the control group respectively. The disease free survival is slightly lower in the oncoplastic group (69 vs.73.1% at 10-yr). The difference is not statistically significant. Discussion: We have compared a large series of primary breast cancer patients that have undergone oncoplastic surgery (454) with a control group (908) and they were followed for a prolonged period of time. It provides the best available evidence to suggest that oncoplastic surgery is a safe and reliable treatment option for the managing of invasive breast cancer.